Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis.
Mult Scler J Exp Transl Clin
; 5(3): 2055217319875471, 2019.
Article
en En
| MEDLINE
| ID: mdl-31555463
ABSTRACT
We evaluated the occurrence of infusion-associated reactions, severe adverse events and no evidence of disease activity 3 status of a therapeutic course consisting of natalizumab followed by alemtuzumab in paediatric-onset multiple sclerosis. Five paediatric-onset multiple sclerosis (age range 16-17 years) were followed for a median of 3.9 years (interquartile range 3.1-5.0). At a natalizumab break (mean infusions 25.6 ± 1.3) patients were switched to alemtuzumab and completed the two therapy courses. Few mild/moderate infusion-associated reactions were observed during alemtuzumab infusion. No severe adverse events were detected. Natalizumab followed by alemtuzumab proved to be a well-tolerated therapeutic course in paediatric-onset multiple sclerosis. Moreover, paediatric-onset multiple sclerosis maintained the no evidence of disease activity 3 status throughout the follow-up.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Mult Scler J Exp Transl Clin
Año:
2019
Tipo del documento:
Article
País de afiliación:
Italia